{"address1": "685 Route 202/206 N", "address2": "Suite 301", "city": "Bridgewater", "state": "NJ", "zip": "08807", "country": "United States", "phone": "800 775 7936", "website": "https://vynetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of chronic inflammatory and immune-mediated conditions. Its lead program, repibresib gel (VYN201), is a topically administered small molecule pan bromodomain (BD) extra-terminal (BET) inhibitor soft drug that address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. The company also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.", "fullTimeEmployees": 13, "companyOfficers": [{"maxAge": 1, "name": "Mr. David T. Domzalski", "age": 57, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1012857, "exercisedValue": 0, "unexercisedValue": 36563}, {"maxAge": 1, "name": "Dr. Iain A. Stuart Ph.D.", "age": 51, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 641555, "exercisedValue": 0, "unexercisedValue": 10156}, {"maxAge": 1, "name": "Ms. Mutya  Harsch J.D.", "age": 49, "title": "General Counsel, Chief Legal Officer & Company Secretary", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 624640, "exercisedValue": 0, "unexercisedValue": 10156}, {"maxAge": 1, "name": "Mr. Tyler  Zeronda CPA", "age": 37, "title": "CFO & Treasurer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Darrell S. Rigel FAAD, M.D.", "age": 73, "title": "Consultant", "yearBorn": 1951, "fiscalYear": 2024, "totalPay": 40200, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.58, "open": 1.6, "dayLow": 1.53, "dayHigh": 1.67, "regularMarketPreviousClose": 1.58, "regularMarketOpen": 1.6, "regularMarketDayLow": 1.53, "regularMarketDayHigh": 1.67, "payoutRatio": 0.0, "beta": 1.25, "forwardPE": -1.7586206, "volume": 174806, "regularMarketVolume": 174806, "averageVolume": 134923, "averageVolume10days": 325620, "averageDailyVolume10Day": 325620, "bid": 1.49, "ask": 1.6, "bidSize": 1, "askSize": 1, "marketCap": 23271146, "fiftyTwoWeekLow": 1.53, "fiftyTwoWeekHigh": 4.3, "priceToSalesTrailing12Months": 46.449394, "fiftyDayAverage": 2.2593, "twoHundredDayAverage": 2.29801, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -38145912, "profitMargins": 0.0, "floatShares": 11040535, "sharesOutstanding": 15209900, "sharesShort": 150482, "sharesShortPriorMonth": 139805, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0099, "heldPercentInsiders": 0.09372, "heldPercentInstitutions": 0.51021, "shortRatio": 2.1, "shortPercentOfFloat": 0.01, "impliedSharesOutstanding": 15209900, "bookValue": 3.512, "priceToBook": 0.4356492, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -39807000, "trailingEps": -0.93, "forwardEps": -0.87, "lastSplitFactor": "1:18", "lastSplitDate": 1676246400, "enterpriseToRevenue": -76.14, "enterpriseToEbitda": 0.874, "52WeekChange": -0.5064516, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.53, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.1875, "targetMedianPrice": 5.875, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 61516000, "totalCashPerShare": 4.044, "ebitda": -43633000, "totalDebt": 99000, "quickRatio": 4.151, "currentRatio": 4.348, "totalRevenue": 501000, "debtToEquity": 0.19, "revenuePerShare": 0.012, "returnOnAssets": -0.33141, "returnOnEquity": -0.56536, "grossProfits": 501000, "freeCashflow": -16997124, "operatingCashflow": -33972000, "revenueGrowth": 0.105, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -152.0238, "financialCurrency": "USD", "symbol": "VYNE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -3.1645615, "regularMarketPrice": 1.53, "marketState": "PRE", "shortName": "VYNE Therapeutics Inc.", "longName": "VYNE Therapeutics Inc.", "fiftyDayAverageChange": -0.7293, "fiftyDayAverageChangePercent": -0.32279912, "twoHundredDayAverageChange": -0.76801014, "twoHundredDayAverageChangePercent": -0.3342066, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Menlo Therapeutics Inc.", "nameChangeDate": "2025-04-01", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1516890600000, "preMarketChange": 0.04000008, "preMarketChangePercent": 2.6143844, "preMarketPrice": 1.57, "regularMarketChange": -0.05000007, "regularMarketDayRange": "1.53 - 1.67", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 134923, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "1.53 - 4.3", "fiftyTwoWeekHighChange": -2.7700002, "fiftyTwoWeekHighChangePercent": -0.6441861, "fiftyTwoWeekChangePercent": -50.64516, "earningsTimestamp": 1741266000, "earningsTimestampStart": 1746621000, "earningsTimestampEnd": 1747053000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.93, "epsForward": -0.87, "corporateActions": [], "preMarketTime": 1743595200, "regularMarketTime": 1743537601, "exchange": "NCM", "messageBoardId": "finmb_6511914", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "VYNE Therapeutics", "trailingPegRatio": null}